CA2396709A1 - Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire - Google Patents
Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire Download PDFInfo
- Publication number
- CA2396709A1 CA2396709A1 CA002396709A CA2396709A CA2396709A1 CA 2396709 A1 CA2396709 A1 CA 2396709A1 CA 002396709 A CA002396709 A CA 002396709A CA 2396709 A CA2396709 A CA 2396709A CA 2396709 A1 CA2396709 A1 CA 2396709A1
- Authority
- CA
- Canada
- Prior art keywords
- recombinant
- hiv
- virus
- envelope protein
- rhabdovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010061598 Immunodeficiency Diseases 0.000 title claims abstract description 59
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims abstract description 59
- 230000007813 immunodeficiency Effects 0.000 title claims abstract description 59
- 241000700605 Viruses Species 0.000 title claims description 73
- 229960004854 viral vaccine Drugs 0.000 title description 5
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 201
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 176
- 101710091045 Envelope protein Proteins 0.000 claims abstract description 76
- 101710188315 Protein X Proteins 0.000 claims abstract description 76
- 230000003612 virological effect Effects 0.000 claims abstract description 38
- 230000028993 immune response Effects 0.000 claims abstract description 35
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims abstract description 34
- 238000013518 transcription Methods 0.000 claims abstract description 24
- 230000035897 transcription Effects 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 16
- 230000000890 antigenic effect Effects 0.000 claims abstract description 11
- 230000004927 fusion Effects 0.000 claims abstract description 7
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract 11
- 239000013598 vector Substances 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 238000000034 method Methods 0.000 claims description 48
- 108090000288 Glycoproteins Proteins 0.000 claims description 45
- 102000003886 Glycoproteins Human genes 0.000 claims description 38
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 30
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 29
- 241000124008 Mammalia Species 0.000 claims description 28
- 241001493065 dsRNA viruses Species 0.000 claims description 28
- 230000004044 response Effects 0.000 claims description 28
- 229960005486 vaccine Drugs 0.000 claims description 28
- 150000007523 nucleic acids Chemical group 0.000 claims description 25
- 230000005923 long-lasting effect Effects 0.000 claims description 19
- 230000003472 neutralizing effect Effects 0.000 claims description 18
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 230000005875 antibody response Effects 0.000 claims description 14
- 230000001086 cytosolic effect Effects 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 12
- 230000002950 deficient Effects 0.000 claims description 11
- 230000006698 induction Effects 0.000 claims description 10
- 230000024932 T cell mediated immunity Effects 0.000 claims description 9
- 230000036039 immunity Effects 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 208000002113 immunodeficiency without anhidrotic ectodermal dysplasia Diseases 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 7
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000036755 cellular response Effects 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 108050001488 Rhabdovirus glycoproteins Proteins 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 abstract description 40
- 241000699670 Mus sp. Species 0.000 abstract description 35
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 12
- 239000013604 expression vector Substances 0.000 abstract description 11
- 230000008348 humoral response Effects 0.000 abstract description 9
- 239000013603 viral vector Substances 0.000 abstract description 9
- 238000011081 inoculation Methods 0.000 abstract description 7
- 238000006386 neutralization reaction Methods 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 102
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 65
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 34
- 241000700618 Vaccinia virus Species 0.000 description 17
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 238000002649 immunization Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 210000004988 splenocyte Anatomy 0.000 description 12
- 229940033332 HIV-1 vaccine Drugs 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000031886 HIV Infections Diseases 0.000 description 7
- 108700010908 HIV-1 proteins Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 6
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000002238 attenuated effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 101150082239 G gene Proteins 0.000 description 5
- 102000011931 Nucleoproteins Human genes 0.000 description 5
- 108010061100 Nucleoproteins Proteins 0.000 description 5
- 206010037742 Rabies Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000009089 cytolysis Effects 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 4
- 241000282553 Macaca Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000037452 priming Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000007982 Phosphoproteins Human genes 0.000 description 3
- 108010089430 Phosphoproteins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000007969 cellular immunity Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000017960 syncytium formation Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229940124718 AIDS vaccine Drugs 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150111062 C gene Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 101150034814 F gene Proteins 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710181600 Glycoprotein gp2 Proteins 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 101000726148 Homo sapiens Protein crumbs homolog 1 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 101000610557 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp31 Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101150090080 I1 gene Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188306 Protein Y Proteins 0.000 description 1
- 102100027331 Protein crumbs homolog 1 Human genes 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 101000825534 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 40S ribosomal protein S2 Proteins 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 101001109965 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L7-A Proteins 0.000 description 1
- 101001109960 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L7-B Proteins 0.000 description 1
- 108010001244 Tli polymerase Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 101800000385 Transmembrane protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 102100040118 U4/U6 small nuclear ribonucleoprotein Prp31 Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- HPNSNYBUADCFDR-UHFFFAOYSA-N chromafenozide Chemical compound CC1=CC(C)=CC(C(=O)N(NC(=O)C=2C(=C3CCCOC3=CC=2)C)C(C)(C)C)=C1 HPNSNYBUADCFDR-UHFFFAOYSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000003139 vital dye staining Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20041—Use of virus, viral particle or viral elements as a vector
- C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne des vecteurs d'expression, à base de souches vaccinales de Rhabdovirus, capables de réplication, recombinés et destinés à exprimer des polypeptides antigéniques viraux hétérologues, tels que les protéines d'enveloppe de virus à déficit immunitaire, ou des sous-parties de celles-ci. On a inséré une unité supplémentaire de départ/arrêt de transcription dans le génome des Rhabdovirus, aux fins d'expression desdits polypeptides antigéniques hétérologues. La protéine gp 160 du VIH-1 est exprimée de façon stable et fonctionnelle, comme indiqué par la fusion des lignées de lymphocytes T humains, après infection par des Rhabdovirus recombinés. L'inoculation de souris à l'aide des virus de la rage recombinés et exprimant la protéine gp 160 du VIH-1 induit une forte réponse humorale dirigée contre la protéine d'enveloppe du VIH-1 après une seule stimulation à l'aide d'une protéine gp 120 du VIH-1 recombinée et isolée. En outre, on a détecté chez ces souris des taux sériques élevés de neutralisation du VIH-1, pouvant aller jusqu'à 1/800. Ces vecteurs viraux recombinés exprimant des polypeptides antigéniques viraux constituent des compositions pharmaceutiques utiles et efficaces dans la production de réponses immunes, spécifiques des virus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49426200A | 2000-01-28 | 2000-01-28 | |
US09/494,262 | 2000-01-28 | ||
PCT/US2001/001989 WO2001055330A2 (fr) | 2000-01-28 | 2001-01-22 | Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2396709A1 true CA2396709A1 (fr) | 2001-08-02 |
Family
ID=23963758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002396709A Abandoned CA2396709A1 (fr) | 2000-01-28 | 2001-01-22 | Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1255849A2 (fr) |
JP (1) | JP2003535577A (fr) |
CN (1) | CN1416471A (fr) |
AU (1) | AU2001229677A1 (fr) |
CA (1) | CA2396709A1 (fr) |
WO (1) | WO2001055330A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1322119C (zh) * | 2002-11-14 | 2007-06-20 | 中国科学院水生生物研究所 | 鳜鱼弹状病毒毒株及制备方法和应用 |
BRPI0411099A (pt) | 2003-06-05 | 2006-07-18 | Wyeth Corp | composições imunogênicas que compreendem os vetores de replicon do vìrus da encefalite eqüina venezuelana e antìgenos de proteìnas de paramixovìrus |
CN105441483B (zh) * | 2005-10-14 | 2019-05-10 | 美国政府健康及人类服务部,疾病控制和预防中心 | 狂犬病病毒组合物和方法 |
US20100278864A1 (en) * | 2005-12-14 | 2010-11-04 | University Of Georgia Research Foundation, Inc. | Rabies Vaccine |
US9889192B2 (en) | 2012-10-01 | 2018-02-13 | Thomas Jefferson University | Immunization with rabies virus vector expressing foreign protein antigen |
CN106802348A (zh) * | 2016-12-30 | 2017-06-06 | 广东华南联合疫苗开发院有限公司 | Sf弹状病毒N蛋白双抗夹心酶联免疫检测试剂盒及方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001634A (en) * | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
WO1996010400A1 (fr) * | 1994-09-30 | 1996-04-11 | The Uab Research Foundation | Vecteurs de therapie genique et vaccins bases sur des virus a arn a brins negatifs non segmentes |
US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
-
2001
- 2001-01-22 JP JP2001561135A patent/JP2003535577A/ja active Pending
- 2001-01-22 CA CA002396709A patent/CA2396709A1/fr not_active Abandoned
- 2001-01-22 WO PCT/US2001/001989 patent/WO2001055330A2/fr not_active Application Discontinuation
- 2001-01-22 EP EP01946888A patent/EP1255849A2/fr not_active Withdrawn
- 2001-01-22 CN CN01804229A patent/CN1416471A/zh active Pending
- 2001-01-22 AU AU2001229677A patent/AU2001229677A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001055330A3 (fr) | 2002-03-28 |
WO2001055330A2 (fr) | 2001-08-02 |
AU2001229677A1 (en) | 2001-08-07 |
CN1416471A (zh) | 2003-05-07 |
EP1255849A2 (fr) | 2002-11-13 |
JP2003535577A (ja) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10793877B2 (en) | Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions | |
Lorin et al. | A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV | |
US8287878B2 (en) | Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof | |
US7993651B2 (en) | Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes | |
Giavedoni et al. | Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection | |
US9731006B2 (en) | Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins | |
JPH06508037A (ja) | 免疫不全ウイルス組換えポックスウイルスワクチン | |
KR19990087126A (ko) | 합성 사람 면역결핍 바이러스 유전자 | |
Ahmad et al. | Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus | |
Guerbois et al. | Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160ΔV1V2 is strongly immunogenic | |
KR20160022919A (ko) | 수포성 구내염 바이러스의 변형된 기질 단백질 | |
CA2799469C (fr) | Affaiblissement par effet de synergie du virus de la stomatite vesicula re (vsv), vecteurs correspondants, et compositions immunogenes correspo dantes | |
ES2634144T3 (es) | Vectores de transferencia lentivíricos defectuosos que no se integran para vacunas | |
WO2012038832A2 (fr) | Génération de particules recombinantes chimères virus de la rougeole - rétrovirus | |
CA2396709A1 (fr) | Rhabdovirus recombines utiles en tant que vaccins a virus vivants diriges contre des virus a deficit immunitaire | |
US20030124146A1 (en) | Recombinant Rhabdoviruses as live-viral vaccines | |
WO2002098457A2 (fr) | Rhabdovirus recombinants en tant que vaccins antiviraux actifs pour des virus de l'immunodeficience | |
Lorin et al. | A paediatric vaccination vector based on live attenuated measles vaccine | |
Foley | Rhabdovirus-based vectors as an HIV-1 vaccine | |
McGettigan Jr | Cellular immune responses against HIV-1 proteins expressed by a highly attenuated rabies-virus-based vaccine vector | |
Schlehuber | Human immunodeficiency virus epitope display on vesicular stomatitis virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |